Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Germ Cell Tumors

Alan Horwich

艾伦·霍里奇

PhD, FRCP, FRCR

🏢The Royal Marsden NHS Foundation Trust / Institute of Cancer Research(皇家马斯顿NHS基金会信托医院/癌症研究所)🌐UK

Emeritus Professor of Radiotherapy; Consultant Clinical Oncologist放射治疗荣休教授;临床肿瘤顾问医师

52
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Pioneering figure in testicular seminoma management at the Royal Marsden spanning four decades. Led foundational MRC trials establishing reduced radiotherapy fields and doses for seminoma, and early surveillance programs that minimized long-term toxicity while maintaining excellent cure rates.

Share:

🧪Research Fields 研究领域

Germ Cell Tumors生殖细胞肿瘤
Testicular Cancer睾丸癌
Radiotherapy放射治疗

🎓Key Contributions 主要贡献

Seminoma Radiotherapy Field Reduction

Led MRC TE10 and TE18 trials demonstrating that para-aortic-only radiotherapy was as effective as dog-leg fields for stage I seminoma, substantially reducing gonadal and bowel irradiation.

Active Surveillance for Stage I Seminoma

Pioneered early surveillance programs at the Royal Marsden for stage I seminoma, demonstrating high salvage rates at relapse and establishing surveillance as a safe management option.

Seminoma Chemotherapy vs. Radiotherapy

Contributed to early MRC trials comparing carboplatin adjuvant therapy to radiotherapy in stage I seminoma, influencing the adoption of carboplatin as a radiotherapy alternative.

Representative Works 代表性著作

[1]

Para-aortic Versus Dog-leg Radiotherapy for Stage I Seminoma (MRC TE10)

Journal of Clinical Oncology (1999)

Randomized trial demonstrating equivalent relapse rates with reduced para-aortic-only radiotherapy field, sparing pelvic structures and reducing long-term toxicity.

[2]

Surveillance After Orchiectomy for Stage I Seminoma

Journal of Clinical Oncology (1992)

Established the safety and efficacy of surveillance for stage I seminoma, showing >99% cause-specific survival with salvage therapy at relapse.

[3]

Optimal Radiotherapy Dose in Stage I and II Seminoma (MRC TE18)

European Journal of Cancer (2011)

Confirmed 20 Gy as adequate radiotherapy dose for stage I seminoma, reducing toxicity vs. historical 30 Gy without compromising relapse-free survival.

🏆Awards & Recognition 奖项与荣誉

🏆Royal College of Radiologists Gold Medal
🏆British Oncological Association Lifetime Achievement Award
🏆Institute of Cancer Research Medal for Distinguished Contribution

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 艾伦·霍里奇 的研究动态

Follow Alan Horwich's research updates

留下邮箱,当我们发布与 Alan Horwich(The Royal Marsden NHS Foundation Trust / Institute of Cancer Research)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment